Moderna reports ‘robust’ COVID vaccine response in children aged 6-11

US pharmaceutical giant Moderna on Monday reported a “robust neutralizing antibody response” to its COVID vaccine in children aged 6-11, and said that it will submit the trial data to global regulators soon.,

COVID-19 vaccine
Credit: Pixabay/CC0 Public Domain

US pharmaceutical giant Moderna on Monday reported a “robust neutralizing antibody response” to its COVID vaccine in children aged 6-11, and said that it will submit the trial data to global regulators soon.

“We are encouraged by the immunogenicity and safety profile of mRNA-1273 in children aged 6 to under 12 years and are pleased that the study met its primary immunogenicity endpoints,” chief executive Stephane Bancel said in a statement.


Explore further


(C) 2021 AFP

Leave a Reply